Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	5,013	3,714	2,248	1,828	1,037	844.29
Revenue Growth	56.17%	65.19%	22.97%	76.23%	22.88%	71.31%
Gross Profit Gross Profit Growth	3,878	3,032	1,925	1,518	868.6	704.14
Operating Income Operating Income Growth	977.59	501.58	-176.89	-282.18	-785.07	-708.65
Net Income Net Income Growth	2,691	313.75	-278.16	-440.24	-1,131	-852.82
Earnings Per Share EPS Growth	19.42	2.33	-2.18	-3.52	-9.30	-7.20
EPS Growth	3190.99%	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
AMVUTTRA AMVUTTRA Growth	3,859	2,314	970.45	557.84	93.8	-
ONPATTRO ONPATTRO Growth	90.23	172.79	252.86	354.55	557.61	474.74
GIVLAARI GIVLAARI Growth	340.44	308.49	255.87	219.25	173.14	127.82
OXLUMO OXLUMO Growth	205.59	191.44	167.05	109.84	69.78	59.59
Roche - Collaboration Roche - Collaboration Growth	149.59	394.88	119.49	337.8	-	-
Regeneron Pharmaceuticals - Collaboration Regeneron Pharmaceuticals - Collaboration Growth	91.52	113.96	302.8	100.47	87.84	113.23
Novartis AG - Collaboration Novartis AG - Collaboration Growth	-	-	79.76	86.73	43.16	49.12
Other - Collaboration Other - Collaboration Growth	0.55	44.53	8.18	21.19	3.91	18.61
Royalty Royalty Growth	276.68	174.02	91.79	40.63	8.18	1.2
Revenue (Total) Revenue (Total) Growth	5,013	3,714	2,248	1,828	1,037	844.29

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	3,587	2,908	2,695	2,439	2,192	2,436
Total Debt Total Debt Growth	2,997	2,969	2,743	2,683	2,613	2,186
Net Cash (Debt) Net Cash Growth	590.4	-60.31	-48.92	-243.24	-420.15	249.87
Net Cash Growth	-	-	-	-	-	-11.29%
Net Cash Per Share Net Cash Per Share Growth	4.25	-0.45	-0.38	-1.95	-3.45	2.11

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	927.69	524.08	-8.31	104.16	-541.27	-641.69
Capital Expenditures CapEx Growth	-149.64	-58.7	-34.28	-62.21	-72.06	-76.37
Free Cash Flow Free Cash Flow Growth	778.05	465.38	-42.59	41.95	-613.33	-718.07
Free Cash Flow Growth	298.10%	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	77.35%	81.64%	85.62%	83.02%	83.73%	83.40%
Operating Margin	19.50%	13.51%	-7.87%	-15.43%	-75.68%	-83.94%
Pretax Margin	16.42%	8.70%	-16.79%	-23.71%	-108.63%	-100.93%
Profit Margin	53.68%	8.45%	-12.37%	-24.08%	-109.04%	-101.01%
FCF Margin	15.52%	12.53%	-1.89%	2.29%	-59.12%	-85.05%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	9.07	167.44	-	-	-	-
Forward PE	20.04	60.03	-	-	-	-
P/FCF Ratio	32.97	112.89	-	572.67	-	-
PS Ratio	5.12	14.15	13.50	13.14	28.18	24.02

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Oct 29, 2026

Data Sources Report a data error